HYLOMORPH’s goal is to prevent all root causes of post-operative complications in implantable medical devices.

Project Description

One in ten people in the Western world is expected to receive at least one implantable medical device in their lifetime.

Post-operative complications of implants (foreign body) threaten the lives of these patients, keep them away from work and family, and place an economical burden on society and the healthcare system.

To address this critical medical need, the HYLOMORPH team has developed a unique surgical membrane that optimizes the interface between implants and human tissue. Manufacturing of the membrane takes place using a patented process combining microengineering and biotechnology, in which non-pathogenic bacteria are cultured within custom-made bioreactors to produce hydrogel films of biosynthetic cellulose, featuring a finely controlled surface topography. In the team’s pre-clinical studies, up to a 5-fold reduction in fibrotic tissue around implants was observed at one year after surgery in the micro-structured biosynthetic cellulose membranes compared with the standard of care. The anti-fibrotic properties and the overall reduction in foreign body reaction are the basic biological mechanisms to improve surgical outcome, prevent the onset of post-operative complications, and help patients in need.

In this project, HYLOMORPH aims to deploy the biosynthetic cellulose membranes in patients receiving cardiac rhythm management devices such as pacemakers and defibrillators.


Faculty Mentor

Volkmar Falk

Portrait HYLOMORPH mentor falk 560

Faculty Mentor

Dimos Poulikakos

Portrait HYLOMORPH mentor poulikakos 560

Partners and Funding

Grants and other:

  • EU Horizon 2020
  • Eurostars/Eureka
  • Innosuisse Grants
  • Innosuisse Label


  • Pioneer fellowship ieLab ETH
  • Venturekick
  • Geneva Smart Invest
  • Efficient Frontiers Invest
  • Verve Ventures
  • Start Angels Network
  • Zürcher Kantonalbank
  • Lichtsteiner Stiftung


Won Swiss Accelerator

Awarded the Swiss Accelerator from Innosuisse as a transitional measure for Horizon Europe. Read more.

Hylomorph secures a CHF 5.2 million Series B

Hylomorph secures a CHF 5.2 million Series-B round led by Geneva Smart Invest and Start Angels Network. Read more.

Encouraging results of Hylomorph’s clinical trial

Receiving positive evaluation by an independent Data Safety Monitoring Board of the clinical safety for the product Hylomate. Read more.

Wyss Zurich project completion

The project exits Wyss Zurich and continues operations in its startup company HYLOMORPH AG.

HYLOMORPH receives Grand from EIC Accelerator

HYLOMORPH is one of the 75 startups and SME across Europe selected by the European Commission out of 1852 applicants. Read more.

EUROSTARS grant by the EU Horizon 2020 program

Hylomorph to receive additional R&D funding from the Eurostars/Eureka program. Read more

HYLOMORPH obtains Innosuisse certification

HYLOMORPH is one of the seven startups receiving the first Innosuisse Certificates.

HYLOMORPH secures CHF 3.2 million Series A funding

The startup announces the finalization of a series A financing round of CHF 3.2 million. Read more.

HYLOMORPH wins the Venture Kick final

Simone Bottan convinces the jury and wins the third and last round of Venture Kick support. Read more.

Wyss Zurich admission

HYLOMORPH is accepted as full project at Wyss Zurich.

HYLOMORPH AG incorporation

The ETH Zurich spin-off HYLOMORPH is incorporated. 

Founding Team

Simone bottan portrait

Simone Bottan

Project Leader & CEO

Aldo ferrari portrait

Aldo Ferrari

Biologist & CSO

Peter jackson portrait

Peter Jackson

Business Development

Francesco robotti portrait

Francesco Robotti

Engineer & COO

Sonia schmocker portrait

Sónia Schmocker

Regulatory, Quality & CRQO

Do you have a breakthrough project you want us to know about?

We invite you to contact the Wyss Zurich office to discuss your project and start the evaluation process.